Authorized purpose: Adravision Perio is semi-automated radiological image-processing software intended to aid dental professionals in measuring mesial and distal bone levels associated with each tooth from bitewing and periapical radiographs; it is labeled for U.S. patients age 22 years or older without remaining primary teeth.
Clinical role
Dental radiograph processing and measurements for professional assessment.
Images and patients
X-ray/Radiography · Teeth and mesial or distal alveolar bone levels
Key limitation
Keep in mind: Use only the exact labeled dental images, patient population, and workflow; output does not replace full patient evaluation or professional diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adravision Perio is semi-automated radiological image-processing software intended to aid dental professionals in measuring mesial and distal bone levels associated with each tooth from bitewing and periapical radiographs; it is labeled for U.S. patients age 22 years or older without remaining primary teeth.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Teeth and mesial or distal alveolar bone levels Input: Supported bitewing, periapical, CT, or MR data specified by the exact submission.
Who uses it?Intended users: Trained dentists, dental hygienists, dental radiologists, or other qualified dental professionals.
What does the software produce?Output: Dental measurements, models, or planning views for professional review.
What is its most important limitation?Key limitation: Use only the exact labeled dental images, patient population, and workflow; output does not replace full patient evaluation or professional diagnosis.
Clinical takeaway. Clinical role: Adravision Perio is semi-automated radiological image-processing software intended to aid dental professionals in measuring mesial and distal bone levels associated with each tooth from bitewing and periapical radiographs; it is labeled for U.S. patients age 22 years or older without remaining primary teeth.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone bench studies on retrospectively collected radiographs (values for bitewing, then periapical): an OKS assessment of 340 radiographs against ground-truther key points (precision 91.0% and 84.8%, recall 94.0% and 89.3%) and a Length Measurement Assessment of 78 radiographs against consensus CAL measurements of three ground truthers (sensitivity 90.7 % and 92.5 %, specificity 94.3 % and 86.8 %, mean absolute error 0.434 mm and 0.504 mm). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adravision Perio is semi-automated radiological image-processing software intended to aid dental professionals in measuring mesial and distal bone levels associated with each tooth from bitewing and periapical radiographs; it is labeled for U.S. patients age 22 years or older without remaining primary teeth.
The exact FDA document reports standalone bench studies on retrospectively collected radiographs (values for bitewing, then periapical): an OKS assessment of 340 radiographs against ground-truther key points (precision 91.0% and 84.8%, recall 94.0% and 89.3%) and a Length Measurement Assessment of 78 radiographs against consensus CAL measurements of three ground truthers (sensitivity 90.7 % and 92.5 %, specificity 94.3 % and 86.8 %, mean absolute error 0.434 mm and 0.504 mm). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Adra completed standalone studies according to the predefined protocols to demonstrate the safety and effectiveness of the Adravision Perio device for its indications for use." … "In the OKS Assessment, Adravision Perio was evaluated with a total dataset of 340 dental radiographs (bitewing and periapical radiographs) and evaluated the precision and recall against the key points labeled by a ground truther". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports standalone bench studies on retrospectively collected radiographs (values for bitewing, then periapical): an OKS assessment of 340 radiographs against ground-truther key points (precision 91.0% and 84.8%, recall 94.0% and 89.3%) and a Length Measurement Assessment of 78 radiographs against consensus CAL measurements of three ground truthers (sensitivity 90.7 % and 92.5 %, specificity 94.3 % and 86.8 %, mean absolute error 0.434 mm and 0.504 mm). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Adra completed standalone studies according to the predefined protocols to demonstrate the safety and effectiveness of the Adravision Perio device for its indications for use." … "In the OKS Assessment, Adravision Perio was evaluated with a total dataset of 340 dental radiographs (bitewing and periapical radiographs) and evaluated the precision and recall against the key points labeled by a ground truther". Read from the exact FDA decision document on 2026-11-14.
Standalone sensitivity for CAL length measurements against three-ground-truther consensus on 78 dental radiographs: 90.7 % (bitewing) and 92.5 % (periapical); no confidence intervals reported.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Adra completed standalone studies according to the predefined protocols to demonstrate the safety and effectiveness of the Adravision Perio device for its indications for use." … "In the Length Measurement Assessment, Adravision Perio was evaluated with a dataset of 78 dental radiographs and evaluated the sensitivity and specificity against the consensus CAL length measurements labeled by three (3) ground truthers within those radiographs.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone specificity for CAL length measurements against three-ground-truther consensus on 78 dental radiographs: 94.3 % (bitewing) and 86.8 % (periapical); no confidence intervals reported.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Adra completed standalone studies according to the predefined protocols to demonstrate the safety and effectiveness of the Adravision Perio device for its indications for use." … "In the Length Measurement Assessment, Adravision Perio was evaluated with a dataset of 78 dental radiographs and evaluated the sensitivity and specificity against the consensus CAL length measurements labeled by three (3) ground truthers within those radiographs.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K232440
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K232440; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K232440; a broader clinical population is not established here.
Scopeexact submission
Tested versionAdravision Perio (K232440)
IndependenceSponsor or vendor study
K232440
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported bitewing, periapical, CT, or MR data specified by the exact submission.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes image input from the radiographic device or the practice management system, or by manual upload into the software, with DICOM, JPEG, TIFF, TIF and BMP among accepted image formats. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Both the proposed device and predicate support image input sources from the radiographic device and the practice management system. The proposed device additionally accepts manual upload of radiographs into the software" … "Both the proposed device and predicate support image formats of JPG, PNG, and JFIF. The proposed device additionally accepts DICOM, JPEG, TIFF, TIF and BMP image formats". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Adravision Perio as software that works on the Edge, Chrome, Firefox, Safari and Brave web browsers. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Both the proposed device and predicate device support common browsers of Edge, Chrome and Firefox. The proposed device additionally works on Safari and Brave.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Dental measurements, models, or planning views for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Adravision Perio as software that works on the Edge, Chrome, Firefox, Safari and Brave web browsers. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Both the proposed device and predicate device support common browsers of Edge, Chrome and Firefox. The proposed device additionally works on Safari and Brave.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes image input from the radiographic device or the practice management system, or by manual upload into the software, with DICOM, JPEG, TIFF, TIF and BMP among accepted image formats. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Both the proposed device and predicate support image input sources from the radiographic device and the practice management system. The proposed device additionally accepts manual upload of radiographs into the software" … "Both the proposed device and predicate support image formats of JPG, PNG, and JFIF. The proposed device additionally accepts DICOM, JPEG, TIFF, TIF and BMP image formats". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Current vendor material is product-family context for K232440 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.
Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.
Modality
X-ray/Radiography
Anatomy
Musculoskeletal and chest/ribs radiographs across specified views
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.